Metastatic triple-negative breast cancer (mTNBC) - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Metastatic triple-negative breast cancer (mTNBC) - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Metastatic triple-negative breast cancer (mTNBC)pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Metastatic triple-negative breast cancer (mTNBC): Overview
Breast cancer (BC) is the most common malignant neoplasm in females. Approximately 10–20% of BCs do not express estrogen and progesterone receptors and lack amplification/overexpression of the human epidermal growth factor 2 receptor (HER2); therefore, they are known as triple-negative breast cancers (TNBCs) and constitute an aggressive histologic subtype. Overall prognosis for patients with mTNBC is worse than for the other BC subtypes, and more effective therapeutic options are needed.
“Metastatic triple-negative breast cancer (mTNBC)- Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic triple-negative breast cancer (mTNBC)pipeline landscape is provided which includes the disease overview and Metastatic triple-negative breast cancer (mTNBC)treatment guidelines. The assessment part of the report embraces, in depth Metastatic triple-negative breast cancer (mTNBC)commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic triple-negative breast cancer (mTNBC)collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic triple-negative breast cancer (mTNBC)R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic triple-negative breast cancer (mTNBC).
Metastatic triple-negative breast cancer (mTNBC)Emerging Drugs Chapters
This segment of the Metastatic triple-negative breast cancer (mTNBC)report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Metastatic triple-negative breast cancer (mTNBC)Emerging Drugs
Trilaciclib: G1 Therapeutics
Trilaciclib is a first-in-class FDA-designated “Breakthrough Therapy“ designed to improve outcomes for people with cancer who are treated with chemotherapy. In June 2019, the company announced preliminary overall survival (OS) data from a randomized Phase 2 trial, which demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone.
Leronlimab (PRO 140): CytoDyn
Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. CytoDyn is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer
Further product details are provided in the report……..
Metastatic triple-negative breast cancer (mTNBC): Therapeutic Assessment
This segment of the report provides insights about the different Metastatic triple-negative breast cancer (mTNBC)drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Metastatic triple-negative breast cancer (mTNBC)
There are approx. 4+ key companies which are developing the therapies for Metastatic triple-negative breast cancer (mTNBC). The companies which have their Metastatic triple-negative breast cancer (mTNBC)drug candidates in the most advanced stage, i.e. phase II include, G1 Therapeutics.
Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
Metastatic triple-negative breast cancer (mTNBC)pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Metastatic triple-negative breast cancer (mTNBC): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic triple-negative breast cancer (mTNBC)therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic triple-negative breast cancer (mTNBC)drugs.
Metastatic triple-negative breast cancer (mTNBC)Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Metastatic triple-negative breast cancer (mTNBC) - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Metastatic triple-negative breast cancer (mTNBC)pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Metastatic triple-negative breast cancer (mTNBC): Overview
Breast cancer (BC) is the most common malignant neoplasm in females. Approximately 10–20% of BCs do not express estrogen and progesterone receptors and lack amplification/overexpression of the human epidermal growth factor 2 receptor (HER2); therefore, they are known as triple-negative breast cancers (TNBCs) and constitute an aggressive histologic subtype. Overall prognosis for patients with mTNBC is worse than for the other BC subtypes, and more effective therapeutic options are needed.
“Metastatic triple-negative breast cancer (mTNBC)- Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic triple-negative breast cancer (mTNBC)pipeline landscape is provided which includes the disease overview and Metastatic triple-negative breast cancer (mTNBC)treatment guidelines. The assessment part of the report embraces, in depth Metastatic triple-negative breast cancer (mTNBC)commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic triple-negative breast cancer (mTNBC)collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic triple-negative breast cancer (mTNBC)R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic triple-negative breast cancer (mTNBC).
Metastatic triple-negative breast cancer (mTNBC)Emerging Drugs Chapters
This segment of the Metastatic triple-negative breast cancer (mTNBC)report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Metastatic triple-negative breast cancer (mTNBC)Emerging Drugs
Trilaciclib: G1 Therapeutics
Trilaciclib is a first-in-class FDA-designated “Breakthrough Therapy“ designed to improve outcomes for people with cancer who are treated with chemotherapy. In June 2019, the company announced preliminary overall survival (OS) data from a randomized Phase 2 trial, which demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone.
Leronlimab (PRO 140): CytoDyn
Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. CytoDyn is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer
Further product details are provided in the report……..
Metastatic triple-negative breast cancer (mTNBC): Therapeutic Assessment
This segment of the report provides insights about the different Metastatic triple-negative breast cancer (mTNBC)drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Metastatic triple-negative breast cancer (mTNBC)
There are approx. 4+ key companies which are developing the therapies for Metastatic triple-negative breast cancer (mTNBC). The companies which have their Metastatic triple-negative breast cancer (mTNBC)drug candidates in the most advanced stage, i.e. phase II include, G1 Therapeutics.
Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Metastatic triple-negative breast cancer (mTNBC)pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Metastatic triple-negative breast cancer (mTNBC): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic triple-negative breast cancer (mTNBC)therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic triple-negative breast cancer (mTNBC)drugs.
Metastatic triple-negative breast cancer (mTNBC)Report Insights
- Metastatic triple-negative breast cancer (mTNBC)Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Metastatic triple-negative breast cancer (mTNBC)drugs?
- How many Metastatic triple-negative breast cancer (mTNBC)drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic triple-negative breast cancer (mTNBC)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic triple-negative breast cancer (mTNBC)therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Metastatic triple-negative breast cancer (mTNBC)and their status?
- What are the key designations that have been granted to the emerging drugs?
- G1 Therapeutics
- CytoDyn
- Trilaciclib
- Leronlimab
Introduction
Executive Summary
Metastatic triple-negative breast cancer (mTNBC): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Metastatic triple-negative breast cancer (mTNBC)– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Metastatic triple-negative breast cancer (mTNBC)companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Metastatic triple-negative breast cancer (mTNBC)Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Trilaciclib: G1 Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Metastatic triple-negative breast cancer (mTNBC)Key Companies
Metastatic triple-negative breast cancer (mTNBC)Key Products
Metastatic triple-negative breast cancer (mTNBC)- Unmet Needs
Metastatic triple-negative breast cancer (mTNBC)- Market Drivers and Barriers
Metastatic triple-negative breast cancer (mTNBC)- Future Perspectives and Conclusion
Metastatic triple-negative breast cancer (mTNBC)Analyst Views
Metastatic triple-negative breast cancer (mTNBC)Key Companies
Appendix
Executive Summary
Metastatic triple-negative breast cancer (mTNBC): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Metastatic triple-negative breast cancer (mTNBC)– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Metastatic triple-negative breast cancer (mTNBC)companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Metastatic triple-negative breast cancer (mTNBC)Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Trilaciclib: G1 Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Metastatic triple-negative breast cancer (mTNBC)Key Companies
Metastatic triple-negative breast cancer (mTNBC)Key Products
Metastatic triple-negative breast cancer (mTNBC)- Unmet Needs
Metastatic triple-negative breast cancer (mTNBC)- Market Drivers and Barriers
Metastatic triple-negative breast cancer (mTNBC)- Future Perspectives and Conclusion
Metastatic triple-negative breast cancer (mTNBC)Analyst Views
Metastatic triple-negative breast cancer (mTNBC)Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Metastatic triple-negative breast cancer (mTNBC)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Metastatic triple-negative breast cancer (mTNBC)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Metastatic triple-negative breast cancer (mTNBC)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Metastatic triple-negative breast cancer (mTNBC)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
